Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Pharmaceutical
An Expert View from Karen Noonan at the Association of Clinical Research Organizations (ACRO) on adopting a more flexible approach to trials moving forward, something made all the more important by the COVID-19 pandemic. 28 September 2020
Pharmaceutical
An Expert View from Jonathan Roses (pictured, left), counsel, Wolf, Greenfield & Sacks, and Matthew Birkett, partner, Hoffmann Eitle, on the granting of two patents for a single invention in the USA and Europe. 22 September 2020
Biotechnology
Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind. Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients—but many patients still need other therapeutic options. 10 September 2020
Pharmaceutical
Just six months into the deadliest global pandemic for a century, the way we live has changed dramatically, most likely forever. For all of us, our children, yours, and mine, above all there will a pre- and post- COVID-19 world. 7 September 2020
Pharmaceutical
In these times especially, but far from exclusively, security of supply remains one of the biggest challenges for pharmaceuticals manufacturers, writes Justin Eames, senior manager, APM Solution Consulting, Aspen Technology, in an Expert View. 27 August 2020
Pharmaceutical
Media headlines are full of hope for potential vaccines and treatments to target SARS-CoV-2, the virus that causes the novel coronavirus disease COVID-19, writes Kate Shaw, the chief executive of UK-based clinical trials patient recruitment company Innovative Trials, in an Expert View. 21 August 2020
Pharmaceutical
Pierre-Georges Roy, partner at M&A advisor Results International, provides an Expert View on why deals kept being made even as much of society shut down. 18 August 2020
Pharmaceutical
Developments in artificial intelligence (AI) and machine learning (ML) are playing an increasingly influential role in the biotech space, driving the formation of new partnerships ,between the tech and healthcare industries. 3 August 2020
Pharmaceutical
Catherine Penny, partner, and Elizabeth Butler, associate, Stevens and Bolton LLP, provide an Expert View on an important issue thrown up by the pandemic. 24 July 2020
Pharmaceutical
The coronavirus pandemic has put many things on hold as many parts of the world are still under lockdown. Even in countries where things were beginning to open up, like in the U.S., there is an uptick in cases and public health officials are concerned about a second wave. 14 July 2020
Pharmaceutical
Gary Ashford, partner and chartered tax advisor at law firm Harbottle and Lewis, looks at tax issues around clinical research in the UK in an Expert View piece. 9 July 2020
Pharmaceutical
An Expert View from Jonathan Roses, counsel, Wolf, Greenfield & Sacks, and Toby Simpson, partner, Hoffmann Eitle, exploring legal differences between the two major jurisdictions of the USA and Europe that life sciences companies should be aware of. 3 July 2020
Pharmaceutical
Amid the unfamiliar circumstances of the last few months, much has been made of the rapid innovation that businesses up and down the UK have been forced to undertake, writes Jameel Zayed, from innovation funding consultancy Leyton, in an Expert View piece. 15 June 2020
Pharmaceutical
Nicholas Jones and Helen Henderson from intellectual property firm, Withers & Rogers, provide an Expert View on how patent bundling could bring unexpected rewards for innovators. 22 May 2020
Pharmaceutical
There are around 90 vaccines being developed against COVID-19 by research teams in companies and universities across the world, with most experts predicting that an effective vaccine could become available by mid-2021. 11 May 2020
Biotechnology
Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives an overview of some of the growth companies that are currently actively working in the fight against coronavirus in an Expert View piece. 6 May 2020
Pharmaceutical
A Supplementary Protection Certificate (SPC) is an extremely valuable prize for the pharmaceutical patent owner as it extends the patent life of an authorised medicine for up to five years at a time when a successful drug is likely to be well established and at the top of its earning power. 14 April 2020
Pharmaceutical
As companies consider the prospect of long-term disruption caused by the coronavirus, Ali Mosawi, chairman of leading Iraqi pharmaceutical agent Al Hayat, provides an Expert View from 25 years of working in one of the world’s most misunderstood markets. 3 April 2020
Pharmaceutical
An overview of one of the issues that has been brought into focus by the coronavirus (COVID-19) outbreak by Madhav Durbha, group vice president, industry strategy, LLamasoft, in an Expert View piece. 17 March 2020
Biotechnology
US biotech major Gilead Sciences’ recent $4.9 billion buyout of Forty Seven put a spotlight on the latter’s star asset magrolimab, an anti-CD47 monoclonal antibody (MAb), as well as the target CD47, a protein on cancer cells sending out “don’t eat me” signal to avoid phagocytosis by microphages. 13 March 2020
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International, and chair of the Medical Affairs Professional Society (MAPS) board. 29 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Biotechnology
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
Pharmaceutical
An Expert View from Adrienne Rivlin, a partner in LEK’s Healthcare practice. 19 April 2024
Pharmaceutical
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex. 4 April 2024
Biotechnology
An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson. 25 March 2024
Pharmaceutical
An Expert View from Rajan Jethwa, chief executive of Ellipses Pharma. 24 March 2024
Pharmaceutical
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
Pharmaceutical
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
Pharmaceutical
An Expert View from Ross Maclean, Precision Health Economics, Outcomes Research and Head of Medical Affairs,
Precision Value and Health, and the same company's Jon Bambalas, Senior Vice President Business Development, Products Senior Vice President Business Development. 5 February 2024
Pharmaceutical
An Expert View from Bob Tilling, vice president, global sales at Kallik. 23 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze